Stifel – so far - is on the hook for more than $166 million in damages, legal fees and settlements in investor complaints ...

Some investors recently have seen million dollar plus decisions by FINRA arbitration panels involving complex products ...

Panelists on a FINRA arbitration board cited Randy Anderson's claims of age discrimination when questioning UBS's reasons for ...

"I've always really enjoyed what I do," said Henry, who began doing legal work involving municipal securities in 1981.

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that ...

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that FINRA oversees.

Investing.com - Stifel raised its price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $123.00 from $94.00 while maintaining a Buy rating on the stock. The company, currently valued at $5.5 ...

Stifel expressed bullishness on both the product launch and Kalvista’s stock potential, suggesting "meaningful upside given modest buyside expectations" for the newly approved HAE treatment.

In the latest quarter, 4 analysts provided ratings for Stifel Financial SF, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Stifel maintains a positive bias towards Philip Morris due to its multi-category approach, which focuses on smoke-free products.

The Financial Industry Regulatory Authority (Finra) shed 49 wirehouse broker-dealers in 2024, reducing its total membership to 3,249 firms, down from 3,298 in 2023 and 3,435 in 2020, according to ...